Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn


Cannabis referendums won big on election day

Kristoffer Inton  |  09 Nov 2020Text size  Decrease  Increase  |  
Email to Friend

Days after election day, the race to become the next president of the United States was deemed “too close to call” as vote tallying continued across several battleground states. In stark contrast, cannabis won by a landslide in state referendums.

Every ballot measure was approved, as Arizona, Montana, and New Jersey expanded legalisation to recreational cannabis, Mississippi legalised medical cannabis, and South Dakota shockingly approved both medical and recreational cannabis in one day.

Even Oregon’s votes on legalising psilocybin and decriminalising all drugs were approved.

We view the success on all votes as evidence of still-growing acceptance for legalisation among Americans. It also confirms our long-term view for nearly 25 per cent average annual growth for the US recreational market and nearly 15 per cent for the medical market through 2030.

Amongst our coverage, 4-star Curaleaf (CURA), 3-star Green Thumb (GTII), and 4-star Canopy Growth (WEED) immediately benefit from the election outcome. While Canopy only operates in Canada, its standing agreement to acquire US multistate operator, Acreage Holdings, upon a change in federal law gives it economic exposure to Tuesday’s outcome. All three companies already operate in medical cannabis in New Jersey, while Curaleaf also operates in Arizona. When previous states have legalised recreational cannabis, existing medical cannabis operations were entrenched to benefit immediately. 

Three-star Cronos (CRON), 3-star Tilray (TLRY), and 5-star Aurora (ACB) have some exposure to the US but only through hemp-derived CBD. As a result, Tuesday’s outcome will have no direct impact.

Despite its announcement the day after the election to acquire US craft brewer Sweetwater, 5-star Aphria (APHA) will also see no direct impact.

Investing Compass
Listen to Morningstar Australia's Investing Compass podcast
Take a deep dive into investing concepts, with practical explanations to help you invest confidently.
Investing Compass

is an Equity Analyst for Morningstar

© 2022 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend